Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
59%
Phase II Study
45%
Phase I Study
44%
Chemotherapy
36%
Docetaxel
31%
Lung Cancer
28%
Maximum Tolerated Dose
28%
Confidence Interval
26%
Small Cell Lung Cancer
25%
Erlotinib
21%
Temsirolimus
21%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
21%
Dose-limiting Toxicity
20%
Carboplatin-paclitaxel
19%
Carboplatin
19%
Progression-free Survival
19%
Platinum-based Chemotherapy
19%
Stable Disease
18%
Phase II Trial
18%
Solid Tumors
18%
Irinotecan
17%
Platinum-based
16%
Overall Survival
16%
Phase I Trial
16%
Epidermal Growth Factor Receptor
15%
Hazard Ratio
14%
Dose Level
14%
Women in Medicine
14%
Advanced Solid Malignancies
14%
Carfilzomib
14%
Pegylated Liposomal Doxorubicin
14%
Bexarotene
14%
Adjuvant Chemotherapy
14%
Randomized Phase II Trial
14%
Sunitinib
14%
Placebo-controlled
14%
Non-Hispanic White
14%
Racialized Economic Segregation
14%
First-line Therapy
12%
4-cycle
11%
Neutropenia
11%
Placebo
10%
Leukemia
10%
Thrombocytopenia
10%
Clinical Trials
9%
Platelet-derived Growth Factor Receptor (PDGFR)
9%
Combination Chemotherapy
9%
Advanced Stage
9%
Newly Diagnosed
9%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
68%
Chemotherapy
56%
Small Cell Lung Cancer
41%
Solid Malignant Neoplasm
34%
Carboplatin
33%
Lung Cancer
33%
Docetaxel
29%
Diseases
29%
Phase II Trials
28%
Maximum Tolerated Dose
26%
Paclitaxel
25%
Temsirolimus
21%
Irinotecan
21%
Erlotinib
21%
Epidermal Growth Factor Receptor
21%
Adverse Event
18%
Progression Free Survival
18%
Clinical Trial
18%
Overall Survival
14%
Carfilzomib
14%
Sunitinib
14%
Bexarotene
14%
Doxorubicin
14%
Placebo
14%
Nausea and Vomiting
11%
Neoplasm
11%
Neutropenia
11%
Thrombocytopenia
9%
Malignant Neoplasm
8%
Bevacizumab
8%
Phase I Trials
8%
Prostate Cancer
8%
Brain Metastasis
8%
Etoposide
7%
Cisplatin
7%
Diarrhea
7%
Randomized Clinical Trial
7%
Alisertib
7%
Chemotherapy Induced Nausea and Vomiting
7%
Everolimus
7%
Seribantumab
7%
Estramustine
7%
Sulindac Sulfone
7%
Proteasome Inhibitor
7%
Pemetrexed
7%
Immune Checkpoint Inhibitor
7%
Topotecan
7%
Vasculotropin
7%
Gossypol
7%
Rosiglitazone
7%
Medicine and Dentistry
Non Small Cell Lung Cancer
79%
Small Cell Lung Cancer
37%
Lung Cancer
25%
Overall Survival
20%
Carboplatin
20%
Malignant Neoplasm
17%
Phase II Trials
16%
Irinotecan
15%
Medicine
14%
Cancer
14%
Adjuvant Chemotherapy
14%
Carfilzomib
14%
Placebo
14%
Diseases
13%
Paclitaxel
12%
Neoplasm
11%
Radiation Therapy
11%
Adverse Event
11%
Non-Small Cell Lung Cancer
10%
Hazard Ratio
10%
Surveillance, Epidemiology, and End Results
10%
Leukemia
9%
Epidermal Growth Factor Receptor
8%
Docetaxel
8%
Base
8%
Next Generation Sequencing
8%
Brain Metastasis
8%
Etoposide
7%
Progression Free Survival
7%
Proton Therapy
7%
Prevalence
7%
Everolimus
7%
Internal Medicine
7%
Sunitinib
7%
Celecoxib
7%
Cyclooxygenase 2
7%
Erlotinib
7%
Attributable Risk
7%
Prostate Cancer
7%
Sulindac Sulfone
7%
Prostatectomy
7%
Chemotherapy Agent
7%
Estramustine
7%
Clinical Oncology
7%
Treatment Duration
7%
Chemoradiotherapy
7%
Gossypol
7%
Proteasome Inhibitor
7%
Meta-Analysis
7%
Olaratumab
7%